The reality check of modern medicine: Why cutting-edge science struggles to conquer cardiovascular disease

The next time someone tells you that artificial intelligence, or any other new technology, is going to cure every disease, point them to the effort to fight heart attacks and strokes, which together are the largest killer in the developed world. While the pharmaceutical industry has increasingly leaned into high-tech genomic insights and advanced computational modeling to expedite drug development, the recent outcomes from the American Heart Association (AHA) annual meeting serve as a sobering reminder of the gap between biological theory and clinical reality.

On November 8, 2026, researchers and industry analysts gathered to digest the results of two major clinical trials. Both Novartis and Novo Nordisk presented data that failed to meet their primary endpoints, despite robust preclinical evidence suggesting their respective interventions should have significantly mitigated cardiovascular risk. These failures highlight a recurring theme in clinical development: the high-fidelity translation of genetic findings into therapeutic success remains an elusive goal, even as the industry adopts more sophisticated technological tools.

The Genetic Hypothesis and Clinical Disappointment

The pharmaceutical industry has spent the last decade shifting its strategy toward "validated targets"—biological pathways identified through large-scale genomic studies. The logic is compelling: if a specific gene or protein is causally linked to a disease, pharmacologically modulating that target should, in theory, improve patient outcomes.

Novartis’s experience with pelacarsen provides a perfect case study of this paradigm. Pelacarsen is designed to lower lipoprotein(a), or Lp(a), a lipid particle that has long been identified by genetic studies as a major independent risk factor for heart disease. High levels of Lp(a) are hereditary, and for years, clinicians have lamented the lack of a targeted therapy to address it. Novartis invested heavily in an antisense oligonucleotide approach, aiming to silence the gene responsible for the production of Lp(a).

When the data were presented at the AHA conference, the findings were stark. While the drug successfully lowered Lp(a) levels as intended, it failed to produce a statistically significant reduction in the incidence of major adverse cardiovascular events (MACE), such as heart attacks and strokes. This discrepancy between biomarker modulation and clinical efficacy suggests that while we may have mastered the "how" of gene silencing, we are still struggling to understand the "why" of cardiovascular disease progression.

The Inflammation Paradox: Novo Nordisk and Ziltivekimab

Simultaneously, the cardiology community turned its attention to Novo Nordisk’s Zeus trial, which evaluated ziltivekimab, an anti-inflammatory drug targeting the IL-6 cytokine. Inflammation has become a central focus in cardiovascular research, as evidence suggests that arterial plaque instability—the precursor to most heart attacks—is driven by an inflammatory response rather than just cholesterol accumulation.

Ziltivekimab was engineered to dampen this inflammatory response by inhibiting IL-6. Despite strong surrogate data indicating a reduction in high-sensitivity C-reactive protein (hsCRP) levels, the trial failed to demonstrate a clinical benefit in reducing cardiovascular mortality or morbidity. For Novo Nordisk, a company currently riding a wave of success with its GLP-1 receptor agonists for obesity and diabetes, the setback is a reminder of the complexity of systemic inflammation. Unlike targeting a single lipid protein, modulating the immune system carries inherent risks and unpredictable systemic consequences that often confound therapeutic efforts.

Chronology of the Cardiovascular Research Shift

To understand why these failures are so resonant, one must look at the evolution of the field over the last decade:

• 2015–2018: The Genomic Gold Rush: Pharmaceutical companies began aggressively acquiring data sets from large biobanks, such as the UK Biobank and the FinnGen project, to identify targets linked to coronary artery disease.
• 2019–2021: The Precision Medicine Pivot: Major players moved away from "shotgun" approaches, focusing instead on antisense oligonucleotides and monoclonal antibodies aimed at specific, genetically validated proteins.
• 2022–2024: The AI Integration: The industry began integrating generative AI to predict protein folding and drug-target binding, with firms like Isomorphic Labs promising to shorten the discovery timeline from years to months.
• 2025–2026: The Reality Check: Large-scale Phase 3 trials, designed on the back of the 2018–2021 target discovery period, have begun to yield "null" results, forcing a industry-wide reassessment of translational models.

Supporting Data and Statistical Realities

The failures of pelacarsen and ziltivekimab are not isolated incidents. Data from the Tufts Center for the Study of Drug Development indicate that the success rate for cardiovascular drugs entering Phase 3 trials remains lower than in other therapeutic areas like oncology or rare diseases.

Specifically, the "translation gap"—the percentage of drugs that move from promising Phase 2 biomarker data to positive Phase 3 clinical outcomes—has hovered below 15% for cardiovascular medicine over the past five years. When compared to the high-profile success of statins or PCSK9 inhibitors, these latest results suggest that we have effectively "low-hanging fruit" and are now moving into the more complex, redundant biological systems of the human heart and vascular network.

Official Responses and Industry Sentiment

While neither Novartis nor Novo Nordisk has signaled an immediate abandonment of their research programs, the atmosphere at the AHA conference was one of cautious reassessment.

"We are learning that the biology of the arterial wall is far more intricate than simple protein-level intervention," noted one independent lead investigator who participated in the peer-review process of the Novartis data. "We can hit the target, we can move the needle on the biomarker, but the disease state—the architecture of the plaque and the systemic response of the vasculature—is not necessarily fixed by that singular action."

Novartis issued a brief statement following the presentation, acknowledging that while the primary endpoint was not met, the company remains committed to "deep-dive analysis" of the trial data to determine if specific patient subgroups experienced benefits that were masked in the overall population. Similarly, representatives from Novo Nordisk emphasized that their broader inflammation research program would continue, albeit with a refined focus on biomarker selection and patient stratification.

The Broader Impact: Implications for Drug Discovery

The implications for the biopharma industry are significant. First, these results are likely to trigger a reevaluation of venture capital and R&D budgets currently flowing toward "AI-first" drug discovery platforms. If AI can predict how to lower a protein but cannot predict whether that lowering will improve a patient’s life, the value proposition of such platforms will be heavily scrutinized.

Second, the results reinforce the need for better "clinical trial simulations." If computational tools are to be truly transformative, they must move beyond protein docking and into whole-body, systems-level modeling. The industry is currently over-reliant on the assumption that a biomarker proxy is a reliable surrogate for patient health. The AHA results provide a mandate to rethink how we design trials, perhaps by incorporating earlier, more rigorous assessments of functional cardiovascular outcomes rather than relying solely on serum-based biomarkers.

Finally, there is the human cost. Millions of patients suffering from cardiovascular disease rely on the promise of innovation. When "miracle" technologies fail to deliver, it does not just impact share prices; it leaves a therapeutic vacuum. The failure of these two drugs means that the standard of care for high-Lp(a) patients and inflammation-driven cardiovascular disease remains unchanged.

As the industry moves forward, the lesson from 2026 is clear: Technology is an amplifier of human intent and scientific strategy, not a replacement for biological wisdom. The path to curing heart disease will require more than just better algorithms; it will require a fundamental humility toward the complexity of human biology. Until we can bridge the divide between what we can measure in a lab and what occurs in the living human heart, the most significant breakthroughs will likely remain on the horizon.